Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Legend Biotech Corporation
  6. Summary
    LEGN   US52490G1022

LEGEND BIOTECH CORPORATION

(LEGN)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
52.71 USD   -2.10%
01/27Legend Biotech Says Phase 3 Trial of Multiple Myeloma Drug Candidate Meets Primary Endpoint; Shares Rise
MT
01/27Legend Biotech Phase 3 Study of Carvykti Meets Primary Endpoint
DJ
01/27Legend Biotech Corporation Announces Research and Development Update
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
53.98(c) 54.23(c) 53.25(c) 53.84(c) 52.71(c) Last
602 118 988 030 512 614 302 760 1 488 208 Volume
-0.46% +0.46% -1.81% +1.11% -2.10% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 135 M - -
Net income 2022 -401 M - -
Net cash position 2022 349 M - -
P/E ratio 2022 -40,4x
Yield 2022 -
Sales 2023 182 M - -
Net income 2023 -388 M - -
Net cash position 2023 340 M - -
P/E ratio 2023 -38,8x
Yield 2023 -
Capitalization 8 824 M 8 824 M -
EV / Sales 2022 62,6x
EV / Sales 2023 46,5x
Nbr of Employees 1 071
Free-Float 5,97%
More Financials
Company
Legend Biotech Corporation is a global, clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly... 
Read more
More about the company
Ratings of Legend Biotech Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about LEGEND BIOTECH CORPORATION
01/27Legend Biotech Says Phase 3 Trial of Multiple Myeloma Drug Candidate Meets Primary Endp..
MT
01/27Legend Biotech Phase 3 Study of Carvykti Meets Primary Endpoint
DJ
01/27Legend Biotech Corporation Announces Research and Development Update
CI
01/27Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleu..
BU
01/27Legend Biotech Corporation Announces Phase 3 CARTITUDE-4 Study of CARVYKTI Has Met Its ..
CI
01/25Barclays Adjusts Legend Biotech's Price Target to $65 From $53, Maintains Overweight Ra..
MT
01/24Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended December ..
PU
01/24Morgan Stanley Adjusts Price Target on Legend Biotech to $65 From $60, Maintains Overwe..
MT
01/03Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
BU
01/03Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Auto..
AQ
01/03Legend Biotech Gets China Okay on New Drug Application for Myeloma Treatment
MT
01/02Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Auto..
BU
01/02Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Auto..
CI
2022China's Easing of COVID Restrictions Trigger Sea of Green Across US Equity Futures
MT
2022Piper Sandler Adjusts Legend Biotech's Price Target to $78 From $72, Maintains Overweig..
MT
More news
News in other languages on LEGEND BIOTECH CORPORATION
01/27Legend Biotech déclare que l'essai de phase 3 du candidat médicament contre le myélome ..
01/27Legend Biotech Corporation annonce une mise à jour sur la recherche et le développement
01/27Legend Biotech Corporation annonce que l'étude de phase 3 CARTITUDE-4 de CARVYKTI a att..
01/03Legend Biotech obtient le feu vert de la Chine pour une demande de nouveau médicament p..
01/02Legend Biotech annonce l'acceptation de sa demande de nouveau médicament pour Ciltacabt..
More news
Analyst Recommendations on LEGEND BIOTECH CORPORATION
More recommendations
ETFs positioned on LEGEND BIOTECH CORPORATIONETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Loncar Cancer Immunotherapy ETF - USD2.86%2.35%-World
Global X MSCI China Health Care ETF - USD1.94%0.71%China
Loncar China BioPharma ETF - Distributing - USD1.63%1.91%China
Virtus LifeSci Biotech Products ETF - USD1.38%1.87%United_States
First Trust US Equity Opportunities - USD1.08%4.92%United_States
More ETFs positioned on LEGEND BIOTECH CORPORATION
Chart LEGEND BIOTECH CORPORATION
Duration : Period :
Legend Biotech Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEGEND BIOTECH CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 52,71 $
Average target price 72,56 $
Spread / Average Target 37,7%
EPS Revisions
Managers and Directors
Ying Huang Chief Executive Officer & Director
Lori Macomber Chief Financial Officer
Fang Liang Zhang Chairman
Guowei Fang SVP, Global Head-Research & Early Development
Liz Gosen Senior Vice President-Global Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
LEGEND BIOTECH CORPORATION5.59%8 824
VERTEX PHARMACEUTICALS11.16%82 513
REGENERON PHARMACEUTICALS, INC.2.88%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008